Litigation Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)
✉ Email this page to a colleague
Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)
| Docket | ⤷ Start Trial | Date Filed | 2022-09-21 |
| Court | District Court, D. Delaware | Date Terminated | 2023-02-06 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. | ||
| Patents | 11,446,252; 9,561,251 | ||
| Attorneys | Brian E. Farnan | ||
| Firms | Farnan LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-09-21 | External link to document | |||
| 2022-09-21 | 1 | Complaint | until after the expiration of U.S. Patent No. 9,561,251 (“the ’251 patent”) together with the expiration …for infringement of U.S. Patent No. 11,446,252 (“the ’252 patent” or “the Patent-in-Suit”) under the laws… THE PATENT-IN-SUIT 6. On September 20, 2022, the United States Patent and Trademark…Switzerland is the assignee of the ’252 patent. A copy of the ’252 patent is attached hereto as Exhibit A. … the ’252 patent, Teva will further infringe at least claims 1, 6, and 11 of the ’252 patent under 35 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
